Annual Reports from the Division of Extramural Activities
Division of Extramural Activities (DEA) annual reports provide insight and useful information about how DEA supports NCI’s mission and the research funding process. A comprehensive look at each of the major areas of responsibility within the Division is provided.
2023
Therapeutic Immune Approaches to Tackling HPV-Associated Malignancies (PDF)
Human papillomavirus (HPV) can cause many different types of tumors. Although work at the National Cancer Institute (NCI) has greatly facilitated important prevention efforts through vaccines, HPV-associated malignancies are still a frequent cause of cancer-related mortality worldwide; however, the non-self viral antigens that remain in these cancers (i.e., E6 and E7) are very immunogenic.
2022
The NCI Program for Natural Product Discovery (PDF)
Unique bioactive molecules from natural sources have contributed significantly to the treatment of cancer.
2021
The discovery of "split genes" and RNA splicing just celebrated its 45th birthday but recently, large scale sequencing of cancer patients has revealed mutations in the spliceosome across cancer types but mostly enriched in the heterogenous collection of diseases known as myeloid malignancies.
2020
Use of Selumetinib to Treat Neurofibromatosis (PDF)
Neurofibromatosis type 1 (NF1) is a common genetic disorder (1:3,000) characterized by a variety of progressive manifestations including the development of tumors called plexiform neurofibromas (PNs), many of which occur in very young children.
Past Reports
To request older annual reports, please contact the Committee Management Office at rawler@mail.nih.gov or 240-276-6420.